Forbion Capital Partners
Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.
Business Model:
Revenue: $0
Employees: 2-10
Rankings
Industries / Tags:
Detailed Forbion Capital Partners Information
Geographic Data
Address: PO Box 5187
City: Naarden
State: flevoland
Zip: 1410
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Twitter
Linkedin
Crunchbase
Metrics
8,335,511Website Global Rank
447Website Monthly Traffic
Twitter Followers
Description
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion&s;s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2021 | Complement Therapeutics | Seed Round | - |
| 7/2017 | Exosome Diagnostics | Series C | 0 |
| 6/2022 | VectivBio | Post-IPO Equity | 0 |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 3/2009 | Pathway Medical Technologies | Series D | 42.5M |
| 11/2013 | Argos Therapeutics | Series E | 0 |
| 7/2005 | Xention | Series B | 13.3M |
| 10/2001 | Ardana Bioscience | Series A | 20M |
| 9/2014 | Pulmologix | Venture Round | 12.4M |
| 4/2012 | Argos Therapeutics | Series D | 0 |
| 3/2010 | Bluebird Bio | Series B | 35M |
| 1/2016 | Exosome Diagnostics | Series B | 0 |
| 1/2021 | New Amsterdam Pharma | Series A | 0 |
| 6/2010 | Cytheris | Series D | 15M |
| 3/2010 | Promedior | Series C | 12M |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 7/2013 | UniQure | Private Equity Round | 0 |
| 4/2007 | CircuLite | Series B | 5M |
| 1/2010 | CircuLite | Series C | 32.5M |
| 9/2009 | arGEN-X | Series A | 13.6M |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 12/2013 | Ario Pharma | Seed Round | 3.1M |
| 3/2014 | Exosome Diagnostics | Series B | 0 |
| 11/2011 | CircuLite | Series D | 30M |
| 8/2007 | AM Pharma | Series C | 3.4M |
| 9/2011 | Amakem | Series A | 25.2M |
| 12/2007 | Santaris Pharma | Series C | 30M |
| 3/2005 | Borean Pharma | Series A | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
| 4/2023 | Complement Therapeutics | Series A | 0 |
| 4/2013 | Allecra Therapeutics | Series A | 19.6M |
| 3/2008 | PanGenetics | Series C | 35.1M |
| 6/2019 | SANIFIT | Series D | 0 |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 2/2017 | Prexton Therapeutics | Series B | 31.1M |
| 6/2015 | Realeve | Series D | 43.2M |
| 6/2016 | Allecra Therapeutics | Series B | 24.8M |
| 8/2022 | F2G | Private Equity Round | 0 |
| 1/2011 | PneumRx | Venture Round | 0 |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 11/2021 | Prilenia | Series B | 0 |
| 5/2012 | Mitralign | Series D | 0 |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 9/2017 | Replimune Group | Series B | 55M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 9/2015 | SANIFIT | Series C | 0 |
| 9/2022 | Pheon Therapeutics | Series A | 0 |
| 7/2021 | NeRRe Therapeutics | Series B | 0 |
| 3/2003 | Acadia Pharmaceuticals Inc. | Series F | 25M |
| 12/2002 | Transave | Series B | - |
| 7/2012 | Bluebird Bio | Series D | 0 |
| 11/2014 | Curetis | Series B | 0 |
| 2/2011 | CellNovo | Series B | 48.3M |
| 9/2015 | Exosome Diagnostics | Series B | 0 |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 2/2013 | Dezima Pharma | Venture Round | 18.6M |
| 1/2020 | NorthSea Therapeutics | Series B | 40M |
| 9/2015 | Replimune Group | Series A | 30M |
| 1/2021 | CoviCept Therapeutics | Seed Round | 2.3M |
| 9/2005 | Bioceros | Private Equity Round | - |
| 6/2020 | Prilenia | Series A | 62.5M |
| 3/2021 | Oxular | Series B | 37M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 10/2021 | Rectify Pharmaceuticals | Series A | 0 |
| 9/2020 | Inversago Pharma | Series B | 0 |
| 6/2021 | VectorY | Seed Round | 0 |
| 10/2004 | FlowMedica | Series C | 0 |
| 5/2010 | Exosome Diagnostics | Series A | 20M |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 11/2006 | Pieris AG | Series B | 0 |
| 8/2009 | NovoGI | Series F | 0 |
| 1/2003 | Impella Cardiosystems | Venture Round | 40M |
| 12/2011 | arGEN-X | Series B | 43.8M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 4/2011 | Bluebird Bio | Series C | 30M |
| 11/2020 | Catalym | Series B | 59.3M |
| 8/2018 | KaNDy Therapeutics | Series C | 32.6M |
| 2/2016 | Akarna | Series B | 15M |
| 11/2011 | Oxyrane | Series D | 26.5M |
| 7/2011 | gIcare Pharma | Series A | 7.4M |
| 3/2012 | Promedior | Series D | 21.5M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 10/2012 | Promedior | Series D | 0 |
| 2/2020 | Azafaros | Series A | 27.5M |
| 5/2015 | Replimune Group | Seed Round | 2M |
| 4/2008 | Transave | Series D | 35M |
| 3/2015 | Rigontec | Series A | 5.2M |
| 5/2023 | Dualyx | Series A | 0 |
| 3/2020 | AM Pharma | Venture Round | 25.4M |
| 3/2009 | BioVex | Venture Round | 40M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 5/2015 | Realeve | Series D | 38M |
| 9/2016 | Rigontec | Series A | 16.9M |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 3/2021 | Gyroscope Therapeutics | Series C | 0 |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 1/2017 | NeRRe Therapeutics | Series B | 28.6M |
| 3/2022 | Precirix | Series B | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 10/2011 | Curetis | Series A | 13.3M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 8/2016 | Catalym | Seed Round | - |
| 12/2017 | NorthSea Therapeutics | Series A | 29.4M |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 3/2018 | Escalier Biosciences | Series B | 19M |
| 2/2022 | Complement Therapeutics | Seed Round | 5.7M |
| 11/2018 | OMEICOS Therapeutics | Series C | 0 |
| 11/2018 | Inflazome | Series B | 45.8M |
| 1/2015 | enGene | Series B | 0 |
| 9/2010 | Cardoz | Series A | 17.6M |
| 6/2012 | Santaris Pharma | Venture Round | 12M |
| 3/2015 | Insmed | Post-IPO Equity | - |
| 3/2023 | Seamless Therapeutics | Seed Round | 0 |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 4/2023 | Complement Therapeutics | Series A | 0 |
| 3/2023 | Seamless Therapeutics | Seed Round | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 11/2022 | CatalYm | Series C | 0 |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 9/2022 | Pheon Therapeutics | Series A | 0 |
| 8/2022 | F2G | Private Equity Round | 0 |
| 6/2022 | VectivBio | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
